Loading
A phase 3 trial of Daratumumab in multiple myeloma, run by Celltrion, now recruiting.
A Study to Compare Pharmacokinetics, Efficacy and Safety of Subcutaneous CT-P44 and Darzalex Faspro in Combination With Lenalidomide and Dexamethasone in Patients With Refractory or Relapsed Multiple Myeloma is a phase 3 interventional study registered as NCT06952478 by Celltrion, with 486 participants planned, started 2025-08-12 and due to reach its primary completion in 2027-11-15. Interventions recorded: CT-P44(Daratumumab), Darzalex Faspro(Daratumumab). Conditions listed: Refractory or Relapsed Multiple Myeloma. No results are recorded here; the registry entry is the source.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Daratumumab, Relapsed or refractory multiple myeloma, Monoclonal antibodies, Multiple myeloma.
Shares Daratumumab, Relapsed or refractory multiple myeloma, Monoclonal antibodies, Multiple myeloma.
Shares Daratumumab, Relapsed or refractory multiple myeloma, Monoclonal antibodies, Multiple myeloma.
Shares Daratumumab, Relapsed or refractory multiple myeloma, Monoclonal antibodies, Multiple myeloma.
Shares Daratumumab, Relapsed or refractory multiple myeloma, Monoclonal antibodies, Multiple myeloma.
Shares Daratumumab, Relapsed or refractory multiple myeloma, Monoclonal antibodies, Multiple myeloma.
Shares Daratumumab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Shares Daratumumab, Relapsed or refractory multiple myeloma, Multiple myeloma.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/